SIRT6 and fatty liver disease: NASH mice have significantly lower levels of SIRT6 in their livers than normal mice, and the absence of SIRT6 in the liver accelerates hepatic steatosis, IR, and inflammation as well as exacerbates NASH-induced hepatic injury, whereas SIRT6 transgenic mice are unaffected by diet-induced NASH (65).